

# AUDIT AND FINANCE COMMITTEE CHAIR REPORT

## ANNEX A: REVIEW OF DECISIONS

BOARD MEETING

**Naguib Kheraj**

7-8 December 2022, Geneva, Switzerland

# Decision 1: Risk Management update (incl. Risk and Assurance Report)

The Gavi Alliance Audit and Finance Committee recommended to the Gavi Alliance Board that it:

- Approve the Draft Risk & Assurance Report 2022 as set out in Annex A of Doc 04, as amended by revisions as requested by the AFC.

# Decision 2: Audit and Investigations report + 2023 plan

The Gavi Alliance Audit and Finance Committee reviewed and approved the Audit and Investigations Plan 2023 as set out in Annex E of Doc 04.

# Decision 3: IFFIm CEPI Arrangement proposal

The Gavi Alliance Audit and Finance Committee **recommended** that the Gavi Alliance Board:

- **Approve** an Assessment Framework exemption to allow funding for CEPI's non-COVID-19 programmes. This exemption shall be applicable only to the transactions related to a single Australian grant (not exceeding AUD 50 million) and a single Spanish grant (not exceeding EUR 75 million) intended for CEPI's support.

# Decision 4: DFC Audit and/or Examination requests

The Gavi Alliance Audit and Finance Committee **approved** the audit and/or examination of Gavi records by employees and officers of DFC, including DFC's right to: (i) examine, copy, and make extracts from, any and all records and documents in the possession or subject to the control of the Borrower relating to its operations and financial affairs, (ii) inspect any of its facilities or properties, and (iii) seek explanations or clarifications from employees and contractors of the Borrower and, with the participation of the Borrower's staff, agents of the Borrower who have or may have knowledge of matters with respect to which DFC seeks information for a period from the date of the finance agreement until the later of 15 March 2026, or the date all amounts due or to become due under it or the related security agreements have been indefeasible paid in full, without the need for further approval by the Audit and Finance Committee.

# Decision 1: Financial forecast 2021-2025 (including COVAX AMC and currency hedging update)

The Gavi Alliance Audit and Finance Committee reviewed the financial forecast and recommended to the Gavi Alliance Board that it:

- a) **Note** that the Audit and Finance Committee reviewed the financial implications of the recommendations made by the Programme and Policy Committee and concluded that these recommendations could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy.
- b) **Approve** the updated Financial Forecast for the Gavi 5.0 (2021-2025) Strategic Period of Qualifying Resources of US\$ 10.4 billion and Forecast Expenditure of US\$ 10.2 billion.
- c) **Approve** the updated Financial Forecast for COVAX AMC (2020-2023) of Qualifying Resources of US\$ 12.5 billion and Forecast Expenditure of US\$ 12.5 billion (made up of US\$ 10.7 billion base expenditure and US\$ 1.8 billion pandemic vaccine pool).
- d) **Approve** the illustrative Financial Forecast for the Gavi 6.0 (2026–2030) Strategic Period of Qualifying Resources of US\$ 8.8 billion and Forecast Expenditure of US\$ 8.5 billion noting that only **existing programmes have been forecast** and the forecast has been prepared to enable the Secretariat to allot funding to these programmes in accordance with the Programme Funding Policy and **does not prejudge future donor contributions or future investment decisions.**

# Decision 2: Partners' Engagement Framework and Secretariat Budget 2023-2024

The Gavi Alliance Audit and Finance Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** US\$ 149.8 million in 2023 and US\$ 152.8 million in 2024 for Secretariat Resources excluding COVAX.
- b) **Approve** US\$ 1.0 million in 2023 and US\$ 1.0 million in 2024 for capital expenditure budgets.
- c) **Approve** the COVAX Operating budget of US\$ 43 million in 2023.
- d) **Approve** the Gavi 5.1 Operating budget for the additional targeted priorities related to the pandemic of US\$ 27.7 million in 2024 noting these additional priorities are subject to Board approval of the Gavi 5.1 strategy.
- e) **Approve** US\$ 73.9 million in 2023 and US\$ 73.1 million in 2024 for the Partners' Engagement Framework budget including
  - i. US\$ 5.2 million in 2023 for COVAX procurement fees;
  - ii. Continuation of US\$ 2 million complexity fee relating to UNICEF procurement of Gavi 5.0 vaccines during the pandemic for both 2023 and 2024;
  - iii. US\$ 2.4 million in 2024 for procurement fees for the additional targeted priorities related to the pandemic.

# Thank you